Copyright held by the owner/author(s).
This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. This work is licensed under a Creative Commons Attribution 4.0 International ...
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
Merck announced today that pembrolizumab (Keytruda) injected subcutaneously is not inferior to intravenous (IV) dosing, currently the drug’s only approved route of administration. In the phase III ...
Major Finding: A dual function supracluster was engineered to increase radiosensitivity and antitumor immunity. Concept: Gold supraclusters carrying siRNA against LGALS1 (galectin-1) reshaped the ...
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
Clin Cancer Res (2024) 30 (21_Supplement): A045.
Search for other works by this author on: ...
1Fred Hutchinson Cancer Center, Seattle, WA.
Bristol Myers Squibb (BMS) faces a $6.7 billion lawsuit alleging that the company purposely delayed approval of Celgene-developed drugs to avoid paying Celgene shareholders owning contingent value ...
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license ...
1RareCyte, Inc., Seattle, WA.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback